Bull
$5.42
情景价格
$3.030
-0.087 (-2.88%)收盘时
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Heart Test Laboratories Inc is a good buy right now due to its recent positive momentum, with a 5-day price change of +8.21% and a strong gross margin of 58.33%. The stock is currently priced at $3.03, and the recent investment of $1 million by Fortitude at a 22% premium shows strong market confidence. However, the main risk is the negative earnings per share (EPS) of -0.88 reported in the last quarter, indicating ongoing profitability challenges.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Fortitude Reports Strong Financial Performance with $20.9 Million Revenue

Fortitude Invests $1 Million in HeartSciences at 22% Premium

Fortitude Acquires $1 Million Stake in HeartSciences

Fortitude Acquires 12.5MW Mining Facility, Advances IPO Plans

Fortitude Secures Major Purchase Agreement with Bitmain for Zcash Miners
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Heart Test Laboratories Inc is a good buy right now due to its recent positive momentum, with a 5-day price change of +8.21% and a strong gross margin of 58.33%. The stock is currently priced at $3.03, and the recent investment of $1 million by Fortitude at a 22% premium shows strong market confidence. However, the main risk is the negative earnings per share (EPS) of -0.88 reported in the last quarter, indicating ongoing profitability challenges.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。